AdvanCell is a clinical stage radiopharmaceutical company developing an innovative pipeline of 212Pb-based Targeted Alpha Therapies for cancer patients. AdvanCell’s platform technology addresses the most significant challenge in Targeted Alpha Therapy – the reliable and scalable supply of isotope. AdvanCell’s novel drug discovery, preclinical processes, and state-of-the-art facilities leverage daily access to 212Pb, the ideal isotope for Targeted Alpha Therapy. For more information, please visit www.advancell.com.au
Company Details
- Employees
- 65
- Founded
- -
- Address
- Level 7, 167 Macquarie Street, Sydney,new South Wales 2000,australia
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.advancell.com.au
- Keywords
- Radiopharmaceuticals, Radioligand Discovery, 212Pb, Biotechnology, Biopharmaceuticals, Changing the Course of Cancer.
- HQ
- Sydney, New South Wales
Advancell Questions
Advancell's website is http://www.advancell.com.au
Advancell's LinkedIn profile is https://www.linkedin.com/company/advancell
Advancell has
65 employees.
View email and phone details for 65
employees at Advancell.
Advancell's industry is
Biotechnology Research
Advancell's top competitors are
Aviceda Therapeutics,
Newleos Therapeutics,
Normunity,
Verdiva Bio,
Ouro Medicines,
Helicore Biopharma,
Timberlyne Therapeutics,
Abcuro, Inc,
Kardigan,
Tenvie Therapeutics.
Advancell's categories are Biotechnology Research
Advancell's founding year is 2019
